---
title: "Maze Therapeutics Announces Positive Phase 1 Trial Results for MZE782, Paving the Way for Phase 2 Trials in PKU and CKD by 2026"
description: "Maze Therapeutics Inc. announced positive Phase 1 trial results for MZE782, an oral small molecule targeting SLC6A19. The trial showed an excellent safety profile and significant pharmacodynamic effec"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256911887.md"
published_at: "2025-09-11T11:30:26.000Z"
---

# Maze Therapeutics Announces Positive Phase 1 Trial Results for MZE782, Paving the Way for Phase 2 Trials in PKU and CKD by 2026

> Maze Therapeutics Inc. announced positive Phase 1 trial results for MZE782, an oral small molecule targeting SLC6A19. The trial showed an excellent safety profile and significant pharmacodynamic effects, including a 42-fold increase in urinary phenylalanine excretion. No serious adverse events were reported. The company plans to start Phase 2 trials in 2026 to further assess MZE782's efficacy in treating phenylketonuria (PKU) and chronic kidney disease (CKD).

Maze Therapeutics Inc. has announced positive results from their Phase 1 clinical trial of MZE782, an oral small molecule targeting the solute transporter SLC6A19. The study, conducted with healthy volunteers, demonstrated an excellent safety profile and significant pharmacodynamic effects, including a 42-fold increase in urinary phenylalanine excretion. This suggests potential therapeutic benefits for patients with phenylketonuria (PKU) and chronic kidney disease (CKD). No serious adverse events were observed. Maze plans to initiate Phase 2 trials in 2026 to further investigate MZE782’s efficacy in reducing plasma phenylalanine levels in PKU and proteinuria in CKD. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527268-en) on September 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [MAZE.US - Maze Therapeutics](https://longbridge.com/en/quote/MAZE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit | Maze Therapeutics (NASDAQ: MAZE) is advancing a genetics-driven drug development approach, focusing on kidney and metabo | [Link](https://longbridge.com/en/news/275972996.md) |
| Maze Therapeutics President and CMO Harold Bernstein Reports Disposal of Common Shares | Harold Bernstein, President and CMO of Maze Therapeutics Inc., reported the disposal of common shares of the company. Th | [Link](https://longbridge.com/en/news/274870273.md) |
| Pivotal Vopimetostat Pancreatic Cancer Trial Plan Might Change The Case For Investing In Tango Therapeutics (TNGX) | Tango Therapeutics, Inc. is advancing vopimetostat into a pivotal 300-patient trial for second-line pancreatic cancer, f | [Link](https://longbridge.com/en/news/276141096.md) |
| ‘They are not forgotten’: Volunteer spends holidays with long-stay IMH patients for 15 years | Mr. Yong Kwon Seng has dedicated 15 years to volunteering at the Institute of Mental Health (IMH) in Singapore, befriend | [Link](https://longbridge.com/en/news/275975042.md) |
| Atossa Therapeutics Completes Reverse Stock Split | Atossa Therapeutics Inc. has completed a reverse stock split effective February 2, 2026, to regain compliance with Nasda | [Link](https://longbridge.com/en/news/275612646.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
